Entera Bio Ltd. (ENTX) stock
ENTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.26+0.26 (+8.67%)
Close on Nov 18, 2026Market cap $564.44MP/E –Yield –
Entera Bio free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Entera Bio's free cash flow for the twelve months ending Jun 30, 2026 was -$10.96M. For fiscal 2025 it was -$7.48M. The highest annual figure on record is -$3.18M in fiscal 2016.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$7.48M | – |
| FY2024 | Dec 31, 2024 | -$6.82M | – |
| FY2023 | Dec 31, 2023 | -$7.33M | – |
| FY2022 | Dec 31, 2022 | -$12.55M | – |
| FY2021 | Dec 31, 2021 | -$9.08M | – |
| FY2020 | Dec 31, 2020 | -$10.61M | – |
| FY2019 | Dec 31, 2019 | -$8.96M | – |
| FY2018 | Dec 31, 2018 | -$9.86M | – |
| FY2017 | Dec 31, 2017 | -$4.58M | – |
| FY2016 | Dec 31, 2016 | -$3.18M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.47M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.09M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.86M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.55M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.66M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.41M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.47M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.15M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.34M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.86M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.62M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.53M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.56M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.62M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.01M | – |
| Q3 FY2022 | Sep 30, 2022 | -$2.87M | – |
| Q2 FY2022 | Jun 30, 2022 | -$2.85M | – |
| Q1 FY2022 | Mar 31, 2022 | -$4.82M | – |
| Q4 FY2021 | Dec 31, 2021 | -$2.52M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.12M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.12M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.32M | – |
See a number that looks wrong?